<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Elan Corporation, PLC News Release</title><link>http://newsroom.elan.com/Phoenix.zhtml?c=88326&amp;p=irol-news</link><description>A Collection of Elan Corporation, PLC News Release</description><language>en-us</language><category>Uncategorized</category><image><title>Elan Corporation, PLC News Release</title><link>http://newsroom.elan.com/Phoenix.zhtml?c=88326&amp;p=irol-news</link><url>http://media.corporate-ir.net/media_files/IROL/88/88326/rss.gif</url></image><lastBuildDate>Fri, 24 May 2013 04:37:30 GMT</lastBuildDate><item><title>Elan Announces Pricing of US$850 Million in Aggregate Principal Amount of Senior Notes Due 2021</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1823946</link><description><![CDATA[DUBLIN--(BUSINESS WIRE)--May. 23, 2013--
      Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced the pricing
      of the offering of US$850 million aggregate principal amount of 6.250%
      Senior Notes due 2021 (the “Notes”) by its wholly-owned subsidiaries,
      Elan Finance public limited company and Elan Finance Corp. The Notes
      will be issued at par. The offering is expected to close on May 31,
      2013, subject to customary closing conditions. The Notes will be fully
      and unconditionally guaranteed by Elan and certain of its existing and
      future subsidiaries. The net proceeds of the Notes offering (plus an
      amount that would accrue on the Note...]]></description><category>Uncategorized</category><guid isPermaLink="false">1823946_NEWS</guid><pubDate>Thu, 23 May 2013 20:27:22 GMT</pubDate></item><item><title>Elan Corporation, plc&amp;#39; s Board of Directors Unanimously Reject Royalty Pharma&amp;#39; s Revised Tender Offer</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1823824</link><description><![CDATA[DUBLIN--(BUSINESS WIRE)--May. 23, 2013--
      Elan Corporation, plc (NYSE: ELN) (Elan) today announced that its Board
      of Directors, after careful review and consideration and with the
      assistance of its executive management team as well as outside financial
      and legal advisors, has determined that privately held investment firm
      Royalty Pharma's revised offer (“Royalty Pharma Offer") announced on
      Monday May 20, 2013 to acquire all of Elan's shares for $12.50 per share
      through its shell subsidiary Echo Pharma Acquisition Limited,
      substantially undervalues the company.
    

      Commenting specifically, Mr. Robert A. Ingram, Chairman of Elan...]]></description><category>Uncategorized</category><guid isPermaLink="false">1823824_NEWS</guid><pubDate>Thu, 23 May 2013 15:40:00 GMT</pubDate></item><item><title>Elan&amp;#39;s Response to Royalty Pharma Announcement</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1822248</link><description><![CDATA[DUBLIN--(BUSINESS WIRE)--May. 20, 2013--
      The Board of Elan Corporation, plc (NYSE : ELN) (Elan) notes today’s
      announcement regarding the revised offer by Echo Pharma Acquisition
      Limited (“Royalty Pharma”) to acquire Elan's shares under Rule 2.5 of
      the Irish Takeover Rules.
    

      The Board of Elan will, as before, in line with its obligations under
      Irish Takeover law, assess the Royalty Pharma announcement and will
      advise its shareholders accordingly. In the meantime, Elan shareholders
      are strongly advised to take no action in relation to the Royalty Pharma
      offer.
    

      The Directors of Elan accept responsibility for th...]]></description><category>Uncategorized</category><guid isPermaLink="false">1822248_NEWS</guid><pubDate>Mon, 20 May 2013 17:00:00 GMT</pubDate></item><item><title>Elan Announces Transactions: Decisively Transforming the Company</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1821859</link><description><![CDATA[Proposed Transactions offer shareholders highly unique investment
        and asset proposition
      
      
        Acquisition of AOP Orphan – a private, orphan disease company
        headquartered in Vienna, Austria
      
      
        Acquires 48% of Newbridge Pharmaceuticals – a private Africa,
        Middle East &amp; Turkey (AfMET) company, headquartered in Dubai, UAE
      
      
        AOP &amp; Newbridge together reach 20%+ of the world’s growing
        population and regions
      
      
        Divestment of ELND005 into Speranza Therapeutics – a private and
        independent Irish company
      
      
        Debt issuance of $800 million to optim...]]></description><category>Uncategorized</category><guid isPermaLink="false">1821859_NEWS</guid><pubDate>Mon, 20 May 2013 06:00:23 GMT</pubDate></item><item><title>Elan Announces Proposed Offering of US$800.0 Million in Aggregate Principal Amount of Senior Notes Due 2021</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1821858</link><description><![CDATA[DUBLIN--(BUSINESS WIRE)--May. 20, 2013--
      Elan Corporation, plc (“Elan”) (NYSE: ELN) today announced that its
      wholly-owned subsidiaries, Elan Finance public limited company (“Elan
      Finance”) and Elan Finance Corp. (“Elan Corp.” and together with Elan
      Finance, the “Issuers”), intend to offer, subject to market conditions,
      US$800.0 million in aggregate principal amount of Senior Notes due 2021
      (the “Notes”). The Notes will be fully and unconditionally guaranteed by
      Elan and substantially all of its subsidiaries. The net proceeds of the
      Notes offering (plus an amount that would accrue on the Notes through a
      specified date) will be dep...]]></description><category>Uncategorized</category><guid isPermaLink="false">1821858_NEWS</guid><pubDate>Mon, 20 May 2013 06:00:23 GMT</pubDate></item><item><title>Elan Announces Publication of Response Document</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1820699</link><description><![CDATA[DUBLIN--(BUSINESS WIRE)--May. 15, 2013--
      Elan Corporation, plc (NYSE : ELN) (Elan) today announces publication of
      a response document in respect of the Echo Pharma Acquisition Limited
      (Royalty Pharma) offer made on May 2, 2013.
    

      The response document is published in accordance with Rules 25 and 30.3
      of the Irish Takeover Rules and the United States tender offer rules. As
      previously advised, the Board of Elan has unanimously, and without
      reservation, rejected the offer by Royalty Pharma. Shareholders are
      strongly advised to take no action in relation to the offer.
    

      A copy of the response document, which is being post...]]></description><category>Uncategorized</category><guid isPermaLink="false">1820699_NEWS</guid><pubDate>Wed, 15 May 2013 21:14:02 GMT</pubDate></item><item><title>Elan Provides Additional Commentary on Elan/Theravance Royalty Participation Agreement</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1818420</link><description><![CDATA[Agreement enables science and therapeutic diversification of the
        Elan business portfolio
      
      
        Transaction provides investment in one approved and three
        additional respiratory programs
      
      
        Transaction expected to be earnings accretive (pre-amortisation)
        from 2014
      
      
        Transaction fully leverages Elan’s unique business and financial
        structure
      
      
        Anticipate single digit tax rate on long term royalty cash flow
        from the four programs
      
      
        Significant after tax margin benefit ‘hard wired’ to shareholders
        through cash dividends
      
      ...]]></description><category>Uncategorized</category><guid isPermaLink="false">1818420_NEWS</guid><pubDate>Mon, 13 May 2013 06:03:30 GMT</pubDate></item><item><title>Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1818419</link><description><![CDATA[Theravance to receive $1.0 billion upfront payment upon closing
    

      Elan to receive a 21% participation interest in potential future
      royalty payments associated with four respiratory programs
    
    SOUTH SAN FRANCISCO, Calif. &amp; DUBLIN--(BUSINESS WIRE)--May. 13, 2013--
      Theravance, Inc. (NASDAQ: THRX) and Elan Corporation, plc (NYSE: ELN)
      today announced that they have entered into a royalty participation
      agreement wherein Elan will purchase a participation interest in
      potential future royalty payments related to four respiratory programs
      partnered with GlaxoSmithKline plc (GSK): RELVAR™ ELLIPTA™/BREO™
      ELLIPTA™, ANORO™ ELLIPT...]]></description><category>Uncategorized</category><guid isPermaLink="false">1818419_NEWS</guid><pubDate>Mon, 13 May 2013 06:02:31 GMT</pubDate></item><item><title>Elan Announces Publication of Notice of 2013 Annual General Meeting &amp; Directors&amp;#39;  Retirement</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1811428</link><description><![CDATA[DUBLIN--(BUSINESS WIRE)--Apr. 25, 2013--
      Elan Corporation, plc (NYSE: ELN) (“Elan” or the “Company”) today
      publishes the Notice of the 2013 Annual General Meeting of the Company
      (the “AGM”). The Notice of AGM together with a Form of Proxy has been
      issued to shareholders. The 2013 AGM will be held at The Shelbourne
      Hotel, 27 St. Stephen’s Green, Dublin 2, Ireland on Thursday, 30 May
      2013 at 10.00 a.m. Details of the business to be transacted at the AGM
      are contained in the Notice. The Notice is available on the Company’s
      website www.elan.com.
      Copies of the Notice have been submitted to the Irish Stock Exchange and
      will shor...]]></description><category>Uncategorized</category><guid isPermaLink="false">1811428_NEWS</guid><pubDate>Thu, 25 Apr 2013 20:05:00 GMT</pubDate></item><item><title>Elan Reports First Quarter 2013 Financial Results</title><link>http://newsroom.elan.com/phoenix.zhtml?c=88326&amp;p=RssLanding&amp;cat=news&amp;id=1810109</link><description><![CDATA[DUBLIN--(BUSINESS WIRE)--Apr. 24, 2013--
      Elan Corporation, plc today reported its first quarter 2013 financial
      results.
    

      Mr. Kelly Martin, CEO, said, “Activity in the first quarter of 2013 was
      primarily strategic and consistent with the principles that have guided
      us for nearly a decade. Those principles include reducing uncontrollable
      risk where possible; taking calculated risk where the probabilities look
      favorable; diversifying across science, therapeutics and geographies;
      avoiding unnecessary infrastructure; properly balancing current income
      and growth with investment in future growth potential; and using our
      Ir...]]></description><category>Uncategorized</category><guid isPermaLink="false">1810109_NEWS</guid><pubDate>Wed, 24 Apr 2013 06:00:53 GMT</pubDate></item></channel></rss>